Sales & Earnings In Brief
This article was originally published in The Tan Sheet
Executive Summary
Pfizer Consumer relies on Alacer addition; Latin America strong for Bayer OTCs; Allegra Japan launch drives Sanofi OTC growth; Herbalife overcomes investor “noise”; Rx slide offsets Merck OTC gains.
You may also be interested in...
Pfizer Posts Weak First Quarter As It Continues To Mull Over A Split
The Big Pharma disappoints investors with a weak first quarter and a failure to come to any decisions about the future structuring of the company. Meanwhile, the company made little progress of note during the quarter.
EU Parliament Stricter Than Council On Medicines And Medical Devices Packaging
The EU Parliament's Environment, Public Health and Food Safety committee takes a compromise position with regards to the Packaging and Packaging Waste Directive. Medicines and medical devices should be exempt, but only until 2035, at which point the European Commission should check whether the development of materials and the recycling process have progressed, and may adjust this exemption accordingly.
Stay Or Exit? Global Health Players Ponder New China Trajectory
It's again the time of year when global CEOs descend on China's capital to discuss strategies. This year, however, the mood is different.